In various human cancers, e.g., lung adenocarcinomas; EGFR gene mutation is present in 10%–20% of the patients with African and European ancestry and thereby serves as an excellent biomarker and therapeutic target.21, 43, 44. This evidence concerns the gene EGFR and cancer.